Overview

Window of Opportunity Study in Colorectal Cancer

Status:
Recruiting

Trial end date:
2022-01-01

Target enrollment:

Participant gender:

Summary

This is a window of opportunity translational study investigating the use of pre-operative pembrolizumab and chemotherapy or chemoradiotherapy in non-metastatic colorectal cancer.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Centre, Singapore

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Capecitabine
Pembrolizumab